by Alyssa Lee | Oct 15, 2025
As dermatology research advances in both innovation and patient demand, DelRicht Research continues to stand out as a trusted partner for sponsors and CROs conducting vitiligo and other pigmentary disorder trials. With 9 vitiligo studies completed in the past five...
by Alyssa Lee | Oct 9, 2025
DelRicht Research is proud to showcase the outstanding performance of our investigators and site teams in a pivotal US-based Phase 3 trial evaluating treatment for gout, a form of inflammatory arthritis that affects more than 9 million adults in the U.S. Over the...
by Alyssa Lee | Oct 6, 2025
DelRicht Research is proud to spotlight the exceptional performance of our investigators and site teams in a U.S.-based Phase 2/3 clinical trial evaluating treatment for androgenetic alopecia (AGA), a condition that affects millions of males and females and is...
by Alyssa Lee | Aug 21, 2025
Fibromyalgia research presents unique challenges for clinical trial sponsors and CROs. From accurately capturing subjective pain outcomes to ensuring long-term patient adherence, trials in this therapeutic area demand both scale and operational precision. DelRicht...
by Alyssa Lee | Aug 15, 2025
The U.S. Food and Drug Administration has approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults. Developed by Tonix Pharmaceuticals, Tonmya is the first new FDA-approved fibromyalgia therapy in over 15 years. As a...
